Gefarnate
Code | Size | Price |
---|
TAR-T7099-50mg | 50mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7099-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7099-100mg | 100mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7099-200mg | 200mg | £162.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome.
CAS:
51-77-4
Formula:
C27H44O2
Molecular Weight:
400.647
Purity:
0.971
SMILES:
CC(C)=CCCC(C)=CCCC(C)=CCCC(=O)OCC=C(/C)CCC=C(C)C
References
Du Y Q , Su T , Hao J Y , et al. Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms[J]. Chinese Medical Journal, 2012, 125.
Dota A , Takaoka-Shichijo Y , Nakamura M . Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models[J]. Clinical ophthalmology (Auckland, N.Z.), 2013, 7(default):211-217.
Ohta Y , Kobayashi T , Imai Y , et al. Effect of Gefarnate on Acute Gastric Mucosal Lesion Progression in Rats Treated with Compound 48/80, a Mast Cell Degranulator, in Comparison with That of Teprenone[J]. Biological & Pharmaceutical Bulletin, 2005, 28(8):1424-1430.